Recommended Prophylaxis for Gonococcal Ophthalmia Neonatorum
The correct answer is A: 0.5% erythromycin ointment should be instilled into the eyes of all newborn infants at birth to prevent gonococcal ophthalmia neonatorum.
FDA-Approved Standard of Care
Erythromycin 0.5% ophthalmic ointment is the only FDA-approved medication for this indication in the United States 1. This is the definitive answer based on current U.S. regulatory approval and USPSTF guidelines.
Clinical Rationale
The USPSTF provides an "A" recommendation (highest grade) for universal prophylactic ocular topical medication for all newborns, concluding there is "high certainty that the net benefits outweigh the harms" 1, 2. This recommendation applies to all newborns without exception.
Why This Matters for Morbidity and Mortality
Gonococcal ophthalmia neonatorum can cause:
- Corneal scarring
- Ocular perforation
- Blindness as early as 24 hours after birth 2
Without prophylaxis, transmission rates from infected mothers to newborns range from 30-50% 2, 3. The intervention is highly effective, reducing incidence by 80-95% 3.
Why Other Options Are Incorrect
Option B (1% erythromycin): This concentration is not the FDA-approved formulation. The approved concentration is specifically 0.5% 1.
Option C (2.5% povidone-iodine): While this may be useful for preventing ophthalmia neonatorum, it has not been approved for use in the United States 1.
Option D (1% silver nitrate): This is no longer available in the United States, though it was historically effective 1, 4.
Important Clinical Caveats
- Tetracycline 1.0% ophthalmic ointment was equally effective but is no longer available in the United States 1
- The evidence shows "convincing evidence that universal prophylaxis of newborns is not associated with serious harms" 1
- Erythromycin causes fewer ocular reactions compared to silver nitrate 5
The answer is definitively A: 0.5% erythromycin ointment - this is both the FDA-approved agent and the concentration specifically recommended by USPSTF guidelines for preventing the serious morbidity of gonococcal ophthalmia neonatorum 1, 2.